Trials / Completed
CompletedNCT02536625
Study of the Impact of Everolimus Treatment on Lymphocytes NK (Natural Killer) Development and Functions for Patients With a Metastatic Breast Cancer (HR+ / HER2/Neu Negative)
RAPANK: Study of the Impact of Everolimus Treatment on the Development and Functions of Lymphocytes NK (Natural Killer), for Patients With a Metastatic Breast Cancer (HR+ / HER2/Neu Negative)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 62 (actual)
- Sponsor
- Centre Leon Berard · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
NK (Natural Killer) cells are important in the fight against tumor, especially for the control of cancer metastasis. The purpose of this prospective study is to evaluate the impact on lymphocytes NK functions and development of an everolimus treatment in women treated for a metastatic breast cancer. In particular, the study of lymphocytes NK functions and development under everolimus treatment could permit to validate an early biomarker of the impact of everolimus on these NK cells.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | prospective study |
Timeline
- Start date
- 2015-10-01
- Primary completion
- 2019-04-01
- Completion
- 2019-12-01
- First posted
- 2015-09-01
- Last updated
- 2021-02-04
Locations
2 sites across 1 country: France
Source: ClinicalTrials.gov record NCT02536625. Inclusion in this directory is not an endorsement.